Johnson & Johnson
Duplicate source posts collapse into one event. Only direct subject-company stories are included in this public hub.
Johnson & Johnson (JNJ) stock has reportedly reached a new 52-week high today. The claim comes from an unverified source. No further details are available.
earnings · Impact 20Morgan Stanley's weekly tracker shows total US prescription growth decelerated to 1.5% YoY for the week ended July 31. Among individual drugs, GILD's Yeztugo stood out: Morgan Stanley sees $1.049B in US sales vs $988M consensus, citing strong persistence and payer coverage. Script counts for BMY, VRTX, and JNJ drugs were stable to slightly higher.
Explore the exact intelligence modules available on every supported company page.
